Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival
Authors
Keywords
-
Journal
Expert Review of Gastroenterology & Hepatology
Volume 11, Issue 1, Pages 75-83
Publisher
Informa UK Limited
Online
2016-11-24
DOI
10.1080/17474124.2017.1264874
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma
- (2016) Francesca Romana Ponziani et al. LIVER INTERNATIONAL
- Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: A systematic review and meta-analysis
- (2015) Omar Abdel-Rahman et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma
- (2015) Giovan Giuseppe Di Costanzo et al. Future Oncology
- Sorafenib treatment in Child–Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors
- (2015) Sadahisa Ogasawara et al. INVESTIGATIONAL NEW DRUGS
- Circulating biomarkers in hepatocellular carcinoma
- (2014) Karen L. Morris et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature
- (2014) Omar Abdel-Rahman et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations
- (2014) Omar Abdel-Rahman et al. ENDOCRINE-RELATED CANCER
- Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis
- (2014) Omar Abdel-Rahman et al. Expert Review of Anticancer Therapy
- Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis
- (2014) Omar Abdel-Rahman et al. Expert Review of Anticancer Therapy
- Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis
- (2014) Omar Abdel-Rahman et al. Future Oncology
- Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study
- (2014) Sangheun Lee et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
- (2014) Maria Reig et al. JOURNAL OF HEPATOLOGY
- Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma
- (2014) Masayoshi Yada WORLD JOURNAL OF GASTROENTEROLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2013) David Moher ANNALS OF INTERNAL MEDICINE
- Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature
- (2013) O. Abdel-Rahman et al. DIGESTIVE DISEASES AND SCIENCES
- Hand-Foot Skin Reaction is Associated with the Clinical Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Sorafenib
- (2013) K. Nakano et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma
- (2013) Ju-Yeon Cho et al. LIVER INTERNATIONAL
- Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis
- (2013) L. Min et al. Cancer Immunology Research
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2012) Bassam Estfan et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma
- (2012) Dominik Bettinger et al. HEPATOLOGY
- Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
- (2012) Taiga Otsuka et al. HEPATOLOGY RESEARCH
- Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses
- (2012) Jean-Luc Raoul et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
- (2012) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study
- (2012) Aziz Zaanan et al. JOURNAL OF HEPATOLOGY
- Diarrhea Is a Positive Outcome Predictor for Sorafenib Treatment of Advanced Hepatocellular Carcinoma
- (2012) Ronald Koschny et al. ONCOLOGY
- Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib
- (2011) F Di Fiore et al. BRITISH JOURNAL OF CANCER
- A single center experience of sorafenib in advanced hepatocellular carcinoma patients
- (2011) Tianqiang Song et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib
- (2010) B. Vincenzi et al. ONCOLOGIST
- Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects
- (2010) Alejandro Forner et al. SEMINARS IN LIVER DISEASE
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- (2008) Manuela Schmidinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now